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Summary
Objectives: We have observed that Western blot analysis with an anti-G1 antibody detects G1-NITEGE product in a disintegrin and metallo-
protease with thrombospondin motifs-4 (ADAMTS4)-digested fetal and mature human and bovine aggrecan, but the neoepitope-speciﬁc anti-
NITEGE antibody only detects this product in digests of mature aggrecan. Our objective was to determine whether enzymatic removal of
O- and/or N-linked oligosaccharides from the fetal products would enable detection of the NITEGE neoepitope with anti-NITEGE antibody.
Methods: Aggrecan was puriﬁed from fetal and mature human and bovine cartilage and digested with: (1) ADAMTS4, (2) ADAMTS4, sialidase
II, and N-glycanase, (3) ADAMTS4, sialidase II, and O-glycanase, or (4) ADAMTS4, sialidase II, and both N- and O-glycanases. Western blot
analysis was performed using anti-G1 and anti-NITEGE antibodies.
Results: When fetal G1-NITEGE products were treated with a combination of ADAMTS4, sialidase II, O-glycanase and N-glycanase, the
resultant products migrated faster on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and the NITEGE neoepitope
was rendered detectable.
Conclusions: It appears that the NITEGE neoepitope is blocked on Western blots by oligosaccharide structures present on Asn368 and
Thr370 of fetal human and bovine aggrecans. Such masking structures do not appear to be present on mature aggrecans from these species.
We suggest that when anti-NITEGE antibody is used in Western analysis, enzyme-linked immunosorbent assay (ELISA), ﬂuorescence-
activated cell sorting (FACS), and immunohistochemistry (IHC), removal of oligosaccharides with appropriate glycosidases may unmask
reactivity that would otherwise go undetected. The implications of these ﬁndings for the much-studied effect of Asn368-linked keratan sulfate
(KS)-based structures on ADAMTS4 and ADAMTS5 activity are discussed.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Aggrecan, which hydrates the collagen network of articular
cartilage, is the major structural component that confers re-
versible compressibility to this tissue1. Aggrecanolysis
appears to be an early and important event in all forms of
arthritis, and therefore the study of aggrecan and its degra-
dation products is of major interest to many groups in arthri-
tis research2. Joint injury in humans induces destructive
aggrecanase activity in knee cartilage, in a process in which
the glycosaminoglycan (GAG)-bearing regions of the aggre-
can are released from the cartilage into the synovial ﬂuid3. It
is now thought that a disintegrin and metalloprotease with
thrombospondin motifs-4 (ADAMTS4) and ADAMTS5 are
responsible for most, if not all of this aggrecanase activity*Address correspondence and reprint requests to: Dr. John D.
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777in human cartilage4,5. Aggrecanases cleave the peptide
bond between Glu373 and Ala374 generating the terminal
product G1-NITEGE373 which can remain in the cartilage
matrix6, be lost into the synovial ﬂuid7, or potentially can
be endocytosed by chondrocytes or other joint tissue cells8.
Since their ﬁrst description9, polyclonal anti-NITEGE
antibodies have been used extensively in Western7,
enzyme-linked immunosorbent assay (ELISA)10, ﬂuores-
cence-activated cell sorting (FACS)8, and immunohisto-
chemistry (IHC)11 formats to study aggrecanolysis in
mouse, rat, porcine, bovine, and human systems. In a previ-
ous study with anti-NITEGE antibodies12, it was shown that
the reactivity of the 368NITEGE373 peptide in a competitive
ELISA could be markedly reduced by altering the sequence
to DITEGE or NIYEGE. This was consistent with loss of an-
tigenicity associated with glycosylation of the Asn368 and
Thr370 residues, previously shown by peptide analysis13.
The aim of the present study was to determine the reasons
for apparent masking of the NITEGE neoepitope in aggre-
canase-digested fetal aggrecan samples. Our results
show that N-linked and O-linked glycans in the interglobular
778 J. E. Frank et al.: Oligosaccharide masked NITEGE neoepitopedomain (IGD) of fetal aggrecans can together block anti-NI-
TEGE antibodies from recognizing the NITEGE neoepitope
on a Western blot.Materials and methods
Fetal and mature human aggrecan samples (A1D1) were supplied by Dr.
Peter Roughley, Shriners Hospital, Montreal, PQ. Bovine aggrecan (A1A1D1
subfraction) from fetal and mature bovine cartilages was provided by Dr.
Larry Rosenberg, Monteﬁore Medical Center, Bronx, NY. G1-NITEGE stan-
dard was derived from fetal human aggrecan digested to completion with
ADAMTS4. Recombinant ADAMTS4 was a gift from Dr. Katy Georgiadis,
Wyeth, Inc., Boston, MA. The antibodies used (anti-G1, anti-NITEGE) were
prepared and used as previously described7.AGGRECAN DIGESTION WITH ADAMTS4Fetal and mature human and bovine aggrecan (all at 500 nM, assuming
an aggrecan molecular weight of 106) were digested with ADAMTS4 as de-
scribed14. Brieﬂy, aggrecan was digested with 100 nM ADAMTS4 in 60 ml of
20 mM Tris, 100 mM NaCl, 10 mM CaCl2, pH 7.5 for 16 h at 37
C. Digestion
was terminated by addition of 5.5 ml of 0.5 M Na acetate, 0.5 M Tris, 100 mM
ethylenediaminetetraacetic acid (EDTA), pH 7.6. GAGs were removed by di-
gestion for 3 h at 37C with 25 mU of protease free chondroitinase ABC (Pro-
teus vulgaris; Seikagaku, Associates of Cape Cod, East Falmouth, MA),
followed by digestion for 1 h at 37C with 0.5 mU of endo-b-galactosidase
(Escherichia freundii; Seikagaku) and 0.5 mU of keratanase II (Bacillus sp.;
Seikagaku), followed by vacuum concentration.DIGESTION WITH SIALIDASE II AND O- AND N-GLYCANASESAfter ADAMTS4 digestion and deglycosylation with chondroitinase ABC
and keratanases, samples were dialyzed into distilled water for 6 h at 4C
and dried in a vacuum concentrator. Dry samples were dissolved in 13 ml
of distilled water, 4 ml of sialidase reaction buffer (50 mM Na phosphate,
pH 6.0) and digested with 20 mU of sialidase II (Clostridium perfringens in
recombinant Escherichia coli; Glyko, Inc., Novato, CA) at 37C for 1 h. Sam-
ples were then digested (37C for 1 h) with endo-a-N-acetylgalactosamini-
dase (Streptococcus pneumoniae recombinant in E. coli; O-Glycanase;
2 mU; Prozyme, Inc., San Leandro, CA), dried and digested with peptide-
N-glycosidase F (Chryseobacterium [Flavobacterium] meningosepticum;











Fig. 1. Western blot analysis of fetal and mature human aggrecan treated
anti-G1 antibody. Lanes 3 and 6 were pfollows: after O-glycanase digestion, the dried samples were reconstituted
in 50 ml of 25 mM sodium phosphate, 50 mM EDTA, 0.1% (w/v) sodium do-
decyl sulfate (SDS), 50 mM beta-mercaptoethanol (pH 7.5) and heated at
100C for 5 min. After cooling, the samples were made 0.75% (v/v) in
nonylphenylpolyethylene glycol (NP-40; SigmaeAldrich, St. Louis, MO)
and digested with 5 mU N-glycanase for 2 h at 37C. Samples were then
dried in a vacuum concentrator. Under the conditions used here it was found
that sialic acid removal with sialidase II was necessary before O-glycanase
was effective in the removal of O-glycans. Subsequent N-glycanase diges-
tion as described removes essentially all N-linked oligosaccharides15.WESTERN BLOT ANALYSISWestern blot analysis was performed as described7. Brieﬂy, dried sam-
ples were resuspended in 15 ml of sample buffer (12 mg of dithiothreitol in
200 ml of 6 M urea, with 200 ml of 20 mM 4-(2-hydroxyethyl) piperazine-1-
ethanesulfonic acid (HEPES), 50 mM KCl, 1 mM EDTA, 1.5 mM MgCl2)
and then heated at 100C for 5 min. Samples were loaded on Tris/glycine
SDS gels (Invitrogen, Carlsbad, CA) and run at 200 V for 42 min. Gels
were transferred at 100 V for 1 h and membranes were blocked for 15 min
in a 1% (w/v) solution of powdered milk in 10 ml of Tris buffered saline
(0.05 M Tris base, 0.9% NaCl, pH 7.6) with 0.05% Tween 20 (TBS-T). Mem-
branes were next incubated overnight in primary antibody (anti-G1 antiserum
at 1:3000 or anti-NITEGE at 1 mg/ml), using a 5% milk solution in TBS-T.
Membranes were washed three times in TBS-T for 5 min and then incubated
for 3 h in secondary antibody (anti-rabbit IgG) at 1:3000, using a 5% milk so-
lution in TBS-T. Membranes were washed three times in TBS-T for 10 min,
and developed in Western blotting detection reagents (ECL (enhanced
chemiluminescent); GE Healthcare, Pittsburgh, PA).Results
Fetal and 68-yr-old human aggrecans were incubated
with and without ADAMTS4 and the products were treated
with chondroitinase ABC and keratanases for Western
analysis with anti-G1 and anti-NITEGE probes (Fig. 1). As
expected, the anti-G1 probe detected the aggrecan sub-
strate bands in the samples incubated without ADAMTS4.
These were predominantly full-length aggrecan (about
400 kDa) in the fetal sample (lane 1) and a mixture of full-
length (about 400 kDa) and C-terminally truncated forms68 yr human
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Fig. 3. Western blot analysis of G1-NITEGE standard (lanes 1) and
of human aggrecan (fetal above and mature below) either not di-
gested (lanes 2) or digested with ADAMTS4 (lanes 3), digested
with ADAMTS4, sialidase II and N-glycanase (lanes 4), digested
with ADAMTS4, sialidase II and O-glycanase (lanes 5), or digested
with ADAMTS4, sialidase II, N-glycanase, and O-glycanase (lanes
6). Blots on the left were probed with anti-G1 antibody and blots on
the right were probed with anti-NITEGE antibody.
779Osteoarthritis and Cartilage Vol. 17, No. 6(at about 300 kDa, 160 kDa, and 100 kDa) in the 68-yr-old
sample (lane 4). The anti-G1 antibody also detected the
new ADAMTS4-generated 64 kDa product in both fetal
(lane 2) and mature (lane 5) samples. The presence of
full-length aggrecan in digested samples shows that the
conditions used achieved only partial (perhaps 50%) diges-
tion of substrate in each case. The G1-reactive 64 kDa
product has been identiﬁed as G1-NITEGE374 in many
studies of this kind with mature human and bovine samples.
To conﬁrm this, we probed the ADAMTS4-digested sam-
ples with anti-NITEGE. We unexpectedly found that while
the 68-yr-old 64 kDa product (and a commonly observed
120 kDa ‘‘dimeric’’ G1-NITEGE product) was readily de-
tected (lane 6, Fig. 1), the similarly abundant fetal product
was not reactive with the anti-NITEGE antibody (lane 3,
Fig. 1). The same results were obtained on a comparison
of fetal and mature bovine aggrecans under similar condi-
tions of incubation and detection (Fig. 2).
The anti-NITEGEantibody reacts primarily with theC-termi-
nal glutamate of the 368NITEGE373 sequence9,12. This hex-
apeptide is normally glycanated at Asn368 and Thr370,
presumably with an N-linked oligosaccharide on Asn368 and
anO-linked oligosaccharide on Thr37013.We therefore tested
the possibility that the lack of reactivity of the fetal G1-NITEGE
product might be due to ‘‘masking’’ of the epitope with such ol-
igosaccharides. We found that the weak anti-NITEGE reactiv-
ity of the fetal 64 kDa product was shifted to about 55 kDawith
the combination of sialidase and N-glycanase treatment, but
that the anti-NITEGE reactivity of the product was not mark-
edly changed (Fig. 3, upper panel). Also the combination of
sialidase and O-glycanase treatments shifted the product to
about 60 kDa but did not markedly alter anti-NITEGE reactiv-
ity. However, the combination of sialidase with both N-glyca-
nase and O-glycanase generated a 55 kDa product with
markedly enhanced reactivity (lane 6, Fig. 3, upper panel).
When this experiment was repeated with mature human ag-
grecan, similar shifts in migration properties were observed,
but there was nomarked change in the anti-NITEGE reactivity
of the products, which was strong in all samples (Fig. 3, lower
panel). A similar experiment with fetal and mature bovine
aggrecans (Fig. 2) showed that ‘‘unmasking’’ of the poorly
reactive fetal G1-NITEGE reactivity also required combined
treatment with sialidase and both N- and O-glycanases.Discussion
The ‘‘unmasking’’ of the NITEGE neoepitope on both hu-
man and bovine fetal G1-NITEGE required removal of bothfetal mature
ADAMTS4 + + +
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Fig. 2. Western blot analysis of fetal and mature bovine aggrecans
treated with one of the following: ADAMTS4 only, lanes 1 and 4;
ADAMTS4 and then N-glycanase, lanes 2 and 5; ADAMTS4,
then sialidase II, O-glycanase and N-glycanase. The blot was
probed with anti-NITEGE antibody.O-linked glycan (by the combination of sialidase II and
O-glycanase) and N-linked glycan. Removal of O-linked gly-
can or N-linked glycan alone changed the migration proper-
ties of the product but did not generate maximum
immunoreactivity. This suggests strongly that the ‘‘mask-
ing’’ is due to the combined effects of both types of oligo-
saccharide. Interestingly, the migration properties of the
G1-NITEGE products generated from both human and bo-
vine mature aggrecan were markedly altered by glycosi-
dase digestions (in a manner similar to the fetal products),
however, these treatments did not markedly alter reactivity
with the anti-NITEGE antibody. This suggests that substitu-
tion at these sites in mature aggrecan is with oligosaccha-
rides (presumably sulfated) that do not mask the
neoepitope from antibody.
The results obtained here on masking of the NITEGE
neoepitope in fetal products appear to be mechanistically
related to those obtained on comparison of the sensitivity
of fetal and mature bovine and human aggrecans to
ADAMTS4 digestion16,17. In those studies, done with either
crude aggrecanase16 (most likely ADAMTS4) or recombi-
nant ADAMTS417, it was found (after complete aggrecan di-
gestion) that less fetal aggrecan than mature aggrecan was
cleaved at the Glu373eAla374 site, although similar de-
grees of cleavage occurred in the chondroitin sulfate-2
(CS-2) domain. Taken together with the present work, these
results suggest that ‘‘masking’’ of the Ala373eGlu374 bond
780 J. E. Frank et al.: Oligosaccharide masked NITEGE neoepitopeby oligosaccharide structures on fetal aggrecan may be
responsible for both reduced cleavage efﬁciency and poor
NITEGE detection. Conversely, ‘‘exposure’’ of this peptide
in mature aggrecan (in the presence of sulfated oligosac-
charides) appears to correlate with both efﬁcient
ADAMTS4-mediated cleavage and good NITEGE detec-
tion. Interestingly, the likely glycans involved in these differ-
ences can be inferred by work on the role of keratan sulfate
(KS) in modifying ADAMTS4 activity. Firstly, it was shown
that removal of KS-based structures (but not CS) from
whole aggrecan prevented ADAMTS4-mediated cleavage
at the Glu373eAla374 bond16. However, addition of KS-
based structures to the N-linked oligosaccharide on the
Asn368 of 368NITEGE373 in recombinant G1-G2 potenti-
ated ADAMTS4-mediated cleavage at Glu373eAla37418.
Indeed, the presence of N-linked KS-based structures on
Asn368 in mature, but not immature bovine aggrecan was
concluded from a study of trypsin-generated KS-substituted
peptides13.
These complimentary observations from different labora-
tories suggest a model in which a sulfated KS-based struc-
ture on Asn368 exerts a strong positive effect on the
capacity of ADAMTS4 to cleave at Glu373eAla374. This
idea is fully supported by the ﬁnding that the Michaelis con-
stant (Km) for ADAMTS4-mediated aggrecanolysis is deter-
mined by an exosite binding interaction presumably through
the thrombospondin-1 (TSP-1) motif19,20 which is not af-
fected by active-site-directed inhibitors21. Presumably the
TSP-1 motif on ADAMTS4 interacts tightly with a sulfated
KS-based structure at Asn368 of native mature aggrecan,
and the absence of this structure (for example on fetal aggre-
can) eliminates this critical catalytic binding interaction. We
observed that relatively high concentrations of ADAMTS4
were necessary to achieve IGD cleavage, whereas CS-do-
main cleavage was achieved at much lower concentrations.
It is also possible that the high concentrations of ADAMTS4
needed might have in part been due to some inactivation of
the recombinant enzyme on prolonged storage.
These marked effects of glycan structures on measure-
ments of the efﬁciency of aggrecanolysis22 and the detec-
tion of G1-NITEGE product on Western blots6 (and
potentially in ELISA10, IHC5 or FACS8) will need to be con-
sidered in future interpretation of the relative aggrecanase
activities of ADAMTS4 and ADAMTS523. Because the
abundance of the NITEGE neoepitope has become
a trusted marker for ADAMTS-dependent cleavage of ag-
grecan, consideration of these potential substrate-glycan-
driven effects on aggrecanase catalytic activity and product
detection6 also represents an important issue to address in
future studies. In this regard, the data and discussion pre-
sented in this paper clearly indicate that conclusions drawn
from aggrecanolysis in one species (e.g., mouse) should
not be over interpreted to indicate that the same enzyme
preferences (e.g., ADAMTS5 vs ADAMTS4) would also ap-
ply in the human, where KS sulfation patterns in the IGD will
be very different from rodents. Thus, it may be that
ADAMTS5-dependent aggrecanolysis predominates over
ADAMTS4 in mouse cartilage24e26 simply because of the
predictable absence of highly sulfated KS chains in the mu-
rine IGD (personal communication, Ron Midura, Cleveland
Clinic). This conclusion is also supported by the ﬁnding
that speciﬁc age-dependent glycan structural changes
(such as KS-like substitution of Asn368) do not appear to
affect the catalytic activity of ADAMTS5 for bovine and hu-
man aggrecan17. For the same reasons, the presence of
highly sulfated KS chains on Asn368 might explain the ap-
parent prominent role for ADAMTS4 in aggrecanolysis inmature bovine27 and human4 cartilage explants. Extrapolat-
ing from these in vitro observations to the likely role of
ADAMTS4 and ADAMTS5 in humans in vivo, it can be sug-
gested that ADAMTS4 is most likely responsible for aggre-
canolysis in cartilage locations/zones where the substrate
aggrecan is substituted with sulfated KS-like structures on
Asn368. However, ADAMTS5 is more likely to play a role
where the aggrecan lacks this speciﬁc glycan. The biosyn-
thetic mechanisms which determine the extent of KS addi-
tion, structural variation, and sulfation at this site are likely
to involve changes in GAG and sulfation precursor supply
as well as modiﬁcation of the prevailing activities of the gly-
cosyl transferases and sulfotransferases involved28.Conﬂict of interest
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